Login / Signup

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.

Andrea G S BugginsAntonella ZucchettoKevin NorrisErika TissinoJerry PoleselZarni SoeDavid John AllsupAnna HockadayPei Loo OwPeter HillmenAndrew RawstronDaniel CatovskyPietro BulianRiccardo BombenDuncan M BairdChristopher D FeganValter GatteiChristopher J Pepper
Published in: Leukemia (2021)
Keyphrases
  • wild type
  • genome wide
  • young adults
  • chronic lymphocytic leukemia
  • newly diagnosed
  • dna methylation